For RA, pJIA and sJIA, ACTEMRA may be used alone or in combination with methotrexate: and in RA, other DMARDs may be used.
General Administration and Dosing Information
Rheumatoid Arthritis
Recommended Adult Intravenous Dosage:
When used in combination with DMARDs or as monotherapy the recommended starting dose is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response.
Recommended Adult Subcutaneous Dosage:
Patients less than 100 kg weight | 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response |
Patients at or above 100 kg weight | 162 mg administered subcutaneously every week |
Giant Cell Arteritis
Recommended Adult Intravenous Dosage:
The recommended dose is 6 mg per kg every 4 weeks in combination with a tapering course of glucocorticoids. ACTEMRA can be used alone following discontinuation of glucocorticoids.
Recommended Adult Subcutaneous Dosage:
The recommended dose is 162 mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids.
A dose of 162 mg given once every other week as a subcutaneous injection, in combination with a tapering course of glucocorticoids, may be prescribed based on clinical considerations.
ACTEMRA can be used alone following discontinuation of glucocorticoids.
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Recommended Adult Subcutaneous Dosage:
The recommended dose of ACTEMRA for adult patients with SSc-ILD is 162 mg given once every week as a subcutaneous injection.
Polyarticular Juvenile Idiopathic Arthritis
Recommended Intravenous PJIA Dosage Every 4 Weeks | |
---|---|
Patients less than 30 kg weight | 10 mg per kg |
Patients at or above 30 kg weight | 8 mg per kg |
Recommended Subcutaneous PJIA Dosage | |
---|---|
Patients less than 30 kg weight | 162 mg once every three weeks |
Patients at or above 30 kg weight | 162 mg once every two weeks |
Systemic Juvenile Idiopathic Arthritis
Recommended Intravenous SJIA Dosage Every 2 Weeks | |
---|---|
Patients less than 30 kg weight | 12 mg per kg |
Patients at or above 30 kg weight | 8 mg per kg |
Recommended Subcutaneous SJIA Dosage | |
---|---|
Patients less than 30 kg weight | 162 mg every two weeks |
Patients at or above 30 kg weight | 162 mg every week |
Cytokine Release Syndrome
Recommended Intravenous CRS Dosage | |
---|---|
Patients less than 30 kg weight | 12 mg per kg |
Patients at or above 30 kg weight | 8 mg per kg |
Alone or in combination with corticosteroids. |
Coronavirus Disease 2019
The recommended dosage of ACTEMRA for adult patients with COVID-19 is 8 mg per kg administered by a 60-minute intravenous infusion.
Administration of Intravenous formulation
Administration of Subcutaneous formulation
Dose Modifications